ArticleCellular and molecular gastroenterology and hepatology2026
Dietary Lauric Acid Suppresses Inflammation, Cholestasis, Hepatocyte Injury, and Senescence in 3,5-Diethoxycarbonyl-1,4-Dihydrocollidine-induced Inflammatory Cholangiopathy.
Article in Cellular and molecular gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
BACKGROUND &
aimsInflammatory cholangiopathies involve complex hepatic cell-cell interactions, contributing to inflammation, cholestasis, oxidative stress, senescence, and bile acid dysregulation. The objective of this proof-of-principle study was to examine the early-stage effects of lauric acid (LA), a dietary fatty acid and precursor of the liver receptor homolog 1 (LRH-1) agonist dilauroylphosphatidylcholine (DLPC), in a 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) diet-induced cholangiopathy model.
methodsWe employed a 3-day DDC diet in male C57/BL6 mice and supplemented it with 20% dietary LA. Liver, primary hepatocytes, and intrahepatic immune cells were analyzed for senescence, oxidative stress, and macrophage polarization.
resultsDDC mice showed elevated liver chemistries, hepatic inflammation (F4/80 histochemistry), ductular reaction, and increased hepatocyte senescence markers. Using liquid chromatography-mass spectrometry metabolomics, we found that DDC liver injury was marked by increased hepatic levels of hydrophobic bile acids and oxidative stress. LA restored bile acid homeostasis and Farnesoid X receptor-LRH-1 signaling in the liver and ileum, reduced oxidative stress, and normalized cholestasis-related gene expression in conjunction with improved liver injury, inflammation, and ductular reaction. DDC mice exhibited enhanced hepatocyte senescence (upregulated Cdkn1a, Cdkn1b, Ccl2) and signal transducer and activator of transcription (STAT) 1 activation, all of which were attenuated by LA. Chromatin immunoprecipitation confirmed STAT1 binding to the senescence Cdkn1b promoter, which was suppressed by LA. Additionally, LA enhanced LRH-1-STAT6 colocalization and signaling in bone marrow-derived macrophages from DDC mice, promoting polarization from pro-inflammatory to anti-inflammatory phenotypes, which was associated with increased STAT6 and LRH-1 activation and STAT6 promoter occupancy at anti-inflammatory genes.
conclusionsThese findings indicate the plausibility of LA's therapeutic potential in inflammatory cholangiopathies, which should be pursued in chronic cholangiopathy models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.